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Various Biginelli compounds (dihydropyrimidinones) have been synthesized eﬃciently and in high yields under mild, solvent-
free, and eco-friendly conditions in a one-pot reaction of 1,3-dicarbonyl compounds, aldehydes, and urea/thiourea/acetyl thiourea
using lithium-acetate as a novel catalyst without the addition of any proton source. Comparative catalytic eﬃciency of lithium-
acetate and polyphosphoric acid to catalyze Biginelli condensation is also studied under neat conditions. The reaction is carried
outin theabsence ofany solvent and representsan improvement oftheclassical Biginelli protocol and an advantage incomparison
with FeCl3·6H2O, NiCl2·6H2Oa n dC o C l 2·6H2O that were used with HCl as a cocatalyst. Compared to classical Biginelli reaction
conditions, the present method has advantages of good yields, short reaction times, and experimental simplicity. The obtained
products have been identiﬁed by spectral (1H NMR and IR) data and their melting points. The prepared compounds are evaluated
for anticancer activity against two human cancer cell lines (lung cancer cell line A549 and breast cancer cell line MCF7).
1.Introduction
Multicomponent reactions (MCRs) have emerged as an eﬃ-
cient and powerful tool in modern synthetic organic chem-
istry because the synthesis of complex organic molecules
from simple and readily available substrates can be achieved
in a very fast and eﬃcient manner without the isolation
of any intermediate [1, 2]. Therefore, the discovery for
new MCRs and improving the already-known MCRs are
of considerable interest. Perusal of literature revealed that
the Biginelli reaction, which was discovered more than a
century ago, is one of the most important MCRs for the
synthesis of dihydropyrimidinones based on acid-catalyzed
three component condensation of β-dicarbonyl compound,
an aldehyde, and urea or thiourea [3, 4].
The development of new strategies for the preparation of
complex molecules in neat conditions is a challenging area of
organic synthesis. The pioneering work of Toda et al. [5]h a s
shown that many exothermic reactions can be accomplished
in high yield by just grinding solids together using mortar
and pestle, a technique known as “grindstone chemistry,”
which is one of the “green chemistry techniques.” Reactions
are initiated by grinding, with the transfer of very small
amounts of energy through friction [6]. In addition to
being energy eﬃcient, grindstone chemistry also results in
high reactivity and less waste products. Such reactions are
simple to handle, reduce pollution, comparatively cheaper
to operate, and may be regarded as more economical and
ecologically favorable procedure in chemistry [7]. Generally,
solid-state reactions occur more eﬃciently and more
selectively than does the solution reaction, since molecules
in the crystals are arranged tightly and regularly [8].
The classical Biginelli reactions were conducted under
stronglyacidicconditions,whichsuﬀerfrompooryields,and2 The Scientiﬁc World Journal
long reaction time and sensitive functional groups are lost
during the reaction conditions. This has lead to the devel-
opment of several new methodologies, which improve the
yields compared to original procedure. These new strategies
involve the combinations of Lewis acids and/or transition
metal salts, for example, BF3·OEt2, montmorillonite (KSF),
polyphosphate esters, and reagents like InCl3 [9], LiBr
[10], TMSCl/NaI [11], LaCl3·7H2O[ 12], CeCl3·7H2O[ 13],
Mn(OAc)3·2H2O[ 14], InBr [15], FeCl3 and HCl [16],
ytterbium triﬂate [17], Iodine [18], ZnCl2 [19], CoCl2 [20],
and so forth. Many Lewis acids and transition metal salts
have been found to catalyze this reaction, but they still have
limitationslikehighcost,limitedavailability,prolongedreac-
tion duration, and the use of strong acids. The combination
of solvents and long reaction time, costly chemicals/catalysts,
makes this method environmentally hazardous. Therefore,
development of simple, eﬃcient, clean, high yielding, and
environmentally friendly approaches using new catalysts for
the synthesis of these compounds is an important task of
organic chemists.
Although the original Biginelli protocol of acid-catalyzed
condensation in ethanol is eﬀective method but still various
modiﬁcations of solvents and catalyst are the subject of
this synthesis. During our quest to develop novel catalysts
for multicomponent reactions, we have found that lithium-
acetate is eﬀective promoter of Biginelli reaction. Literature
survey revealed that so far some metal acetates [21]s e e m
to have been utilized to catalyze Biginelli reactions in the
presence of solvents but lithium-acetate has not been utilized
so far.
As per our ongoing eﬀorts to synthesize privileged class
of compounds [22, 23] and our interest in Lewis acid ap-
plications for the Biginelli reaction, herein we wish to
report for the ﬁrst time a novel, simple, and eﬃcient meth-
odology for the synthesis of 3, 4-dihydropyrimidin-2(1H)-
ones and thiones (DHPMs) by the reaction of aldehydes,1,3-
dicarbonyl compounds, and urea/thiourea using catalytic
amount of lithium-acetate and (polyphosphoric acid) PPA
undersolvent-freeconditions(Scheme 1).Further,compara-
tivecatalyticeﬃciency of lithium-acetate and PPA to catalyze
Biginelli condensation is also studied under neat conditions.
2. Results andDiscussion
The current method not only preserves the “one-pot” proto-
col of Biginelli condensation but also favors environmentally
benign reaction conditions of saving energy consumption.
Literature survey revealed that there is little report [24]o n
its use in the synthesis of DHPMs and this technique is
superior to the existing methods, since grinding does not
require solvents leading to safe and environmental friendly
synthesis. Furthermore, the proposed technique does not
require external heating or cooling at any stage, leading to
energy eﬃcient synthesis providing high yields of products.
In order to optimize the reaction conditions, the syn-
thesis of compound 1 was used as a model reaction and a
mixture of benzaldehyde, ethylacetoacetate, and urea in the
presence of lithium-acetate/PPA was magnetically stirred at
room temperature in diﬀerent solvents (Table 1).
The best yield (73%) was obtained when 0.5 equiv-
alents of lithium-acetate/PPA (entries 3 and 6), 1 equiv-
alents of both benzaldehyde and ethylacetoacetate, and 2
equivalents of urea were magnetically stirred in acetoni-
trile (CH3CN)/Tetrahydrofuran (THF), respectively, for 7-8
hours.
It seems that THF is a much better solvent in PPA
catalyzed reaction (entry 3) whereas CH3CN is better in
lithium-acetate-promoted reaction in terms of yields and
time than all other tested solvents (entry 6). However, under
solvent-freeconditionsreactionwasfastand90–95%yieldof
DHPMs was obtained in 10–15 minutes (Table 2).
Encouraged by these results, and due to increasing
demand in modern organic processes of avoiding expensive
puriﬁcation techniques and large amount of solvents, we
examined the reactivity of our catalysts under solvent-
free conditions. The three component cyclocondensation
reaction was carried out either by stirring a mixture of aro-
matic aldehyde (1 eq.), 1,3-dicarbonyl compounds (1 eq.),
urea/thiourea/acetyl thiourea (2 eq.), and catalytic amount
of lithium-acetate/PPA (0.5 eq.) for 30–35 minutes at 70–
80◦C temperature (Method I) or by grinding the reactants
together for 5–10 minutes at room temperature (Method II).
After the completion of reaction (as monitored by TLC),
the reaction mixture was cooled to room temperature and
poured onto crushed ice, ﬁltered, and recrystallized by using
either ethanol or ethyl acetate and pet ether (1:1) to aﬀord
pure product. As reaction was carried out under solvent-free
conditions,cleanproductsareobtained.Ithasbeenobserved
that yield obtained by Method I is 10–15% better than that
obtained in case of Method II.
With the aim of improving the reaction yields, we at-
tempted to add diﬀerent equivalents of catalyst to the reac-
tion mixture and the best condition to prepare DHPMs was
achieved whenreaction was carried out in the presence of 0.5
eq. of catalyst. The use of large amount of catalyst (1 eq, 1.5
eq., or 2 eq.) does not increase the yields. To check promoter
eﬃciency of catalyst and reproducibility of the reaction,
diﬀerent aldehydes were reacted with urea/thiourea/acetyl
thiourea to give 27 diﬀerent compounds. It was found that
catalysts employed (PPA/Lithium-acetate) diﬀered in their
eﬃciency in terms of yields and purity.
In all cases studied, the three-component reaction pro-
ceeded smoothly to give the corresponding DHPMs (1–27)
in satisfactory yields. Most importantly, aromatic aldehydes
carrying either electron-donating or electron-withdrawing
substituents reacted very well to give the corresponding
DHPMs with high purity in moderate-to-good yields.
Another important feature of this procedure is the tolerance
of various functional groups, such as methoxy, halides, and
hydroxy,tothereactionconditions. Thiourea/acetylthiourea
(entries 2, 8, 13, 15, 19, and 24–27) has been used with simi-
lar success to provide corresponding S-dihydropyrimidinone
analogues, which are also of interest due to their biological
activities. It should be noted that PPA or lithium-acetate
was used as the sole promoter agent in neutral media and
reaction proceeded without using any additional proton
source while for others previously reported [16, 20]h y d r a t e s
of metal halides such as Fe (III), Ni (II), and Co (II), aThe Scientiﬁc World Journal 3
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Table 1: Synthesis of Compound 1 at room temperature in the
presence of PPA and Lithium-acetate in diﬀerent solvents.a
Entry Solvent Catalyst Time (hrs) Yield (%)
1E t O H P P A 4 6 7
2C H 3CN PPA 5 58
3T H F P P A 2 7 3
4 Toluene PPA 8 48
5 EtOH Lithium-Acetate 4 63
6C H 3CN Lithium-Acetate 3 73
7 THF Lithium-Acetate 6 68
8 Toluene Lithium-Acetate 7 43
aThereactionswere carriedout inthepresence ofbenzaldehyde(1.0mmol),
ethyl acetoacetate (1.0mmol), urea (2.0mmol), and PPA or lithium-acetate
(0.5mmol) at room temperature for 6-7hrs.
catalytic amount of conc. HCl was needed as a Bronsted acid
cocatalyst. Melting points of most of synthesized DHPMs
were found to be much closer to reported DHPMs indicating
high purity of the compounds (Table 2). The structure of
all the dihydropyrimidinones prepared is characterized by
IR and 1H NMR and are well correlated with the available
literature data.
2.1. Evaluation of Anticancer Activity. The synthesized com-
pounds 6, 16, 18, 23, 24 were evaluated [31]f o ra n t i c a n c e r
activity against human lung cancer cell line A549 and 2,
3, 7, 12, 22 against human breast cancer cell line MCF7.
The cell lines were grown in RPMI 1640 medium containing
10% fetal bovine serum and 2mM L-glutamine. For present
screening experiment, cells were inoculated into 96 well
microtiter plates in 90μL at plating densities, depending
on the doubling time of individual cell lines. After cell
inoculation, the microtiter plates were incubated at 37◦C,
5% CO2, 95% air, and 100% relative humidity for 24h prior
to addition of experimental drugs. After 24h, one plate of
each cell line was ﬁxed in situ with TCA, to represent a
measurement of the cell population for each cell line at
the time of drug addition (Tz). Experimental drugs were
solubilized in appropriate solvent at 400-fold the desired
ﬁnal maximum test concentration and stored frozen prior
to use. At the time of drug addition, an aliquot of frozen
concentrate was thawed and diluted to 10 times the desired
ﬁnal maximum test concentration with complete medium
containing test article at a concentration of 10−3. Additional
three, 10-fold serial dilutions were made to provide a
total of four drug concentrations plus control. Aliquots
of 10μL of these diﬀerent drug dilutions were added to
the appropriate microtiter wells already containing 90μLo f
medium, resulting in the required ﬁnal drug concentrations.
2.2. Endpoint Measurement. After compound addition,
plates were incubated at standard conditions for 48 hours
and assay was terminated by the addition of cold TCA. Cells
were ﬁxed in situ by the gentle addition of 50μL of cold 30%
(w/v) TCA (ﬁnal concentration, 10% TCA) and incubated
for 60 minutes at 4◦C. The supernatant was discarded; the
plates were washed ﬁve times with tap water and airdried.
Sulforhodamine B (SRB) solution (50μL) at 0.4% (w/v) in
1% acetic acid was added to each of the wells, and plates
were incubated for 20 minutes at room temperature. After
staining, unbound dye was recovered and the residual dye
was removed by washing ﬁve times with 1% acetic acid. The
plates were air-dried. Bound stain was subsequently eluted
with 10mM trizma base, and the absorbance was read on an
ELISA plate reader at a wavelength of 540nm with 690nm
reference wavelengths. Percent growth was calculated on a
plate-by-plate basis for test wells relative to control wells.
P e r c e n tG r o w t hw a se x p r e s s e da st h er a t i oo fa v e r a g e
absorbance of the test well to the average absorbance of the
control wells ∗ 100.
Using the six-absorbance measurements time zero (Tz),
control growth (C) ,a n dt e s tg r o w t hi nt h ep r e s e n c eo fd r u g
at the four concentration levels (Ti), the percentage growth
was calculated at each of the drug concentration levels.
Percentage growth inhibition was calculated as
(Ti−Tz)
(C −Tz)

×100 for concentrations for which Ti
≥ Tz (Ti−Tz) positive or zero,
(Ti−Tz)
Tz

×100 for concentrations for which Ti
<Tz .(Ti−Tz) negative.
(1)
The dose response parameters were calculated for each
test article. Growth inhibition of 50% (GI50) was calculated4 The Scientiﬁc World Journal
Table 2: Physical characterization data of compounds.a
Compound R R1 R2 X PPA Yield (%) LiAc Yield (%) M.P. (◦C)
Found Reported
1 H OEt H O 94 90 198–202 202-203 [25]
2 H OEt H S 88 85 202–204 204–206 [25]
3 4-OCH3 OEt H O 93 91 205–207 199-200 [25]
4 4-OH OEt H O 87 82 224–226 232–234 [25]
5 2-OH OEt H O 85 80 195–200 201–203 [25]
6 3-OH OEt H O 78 81 161–163 163–165 [26]
7 4-Cl OEt H O 92 89 205–208 212-213 [25]
8 4-Cl OEt H S 88 80 208–210 176-177 [27]
9 3-Cl OEt H O 74 72 185–187 190–192 [12]
10 2-Cl OEt H O 78 77 190–192 220–222 [26]
11 2-Cl OMe H O 80 82 245–248 252-253 [28]
12 3-OCH3 OEt H O 92 87 210–212 220-221 [29]
13 3-OCH3 OEt H S 88 84 214–216 —
14 2,4-Dimethyl OEt H O 82 85 200–202 —
15 3,4-dimethyl OEt H S 77 78 203–205 —
16 3-OH, 4-OCH3 OEt H O 84 81 225–227 230–232 [30]
17 3-OCH3, 4-OH OEt H O 88 83 230–232 233–235 [30]
18 3,4,5- Trimethoxy OEt H O 92 88 202–205 216–218 [24]
19 3,4,5- Trimethoxy OMe H S 84 78 187–190 —
20 3,4,5- Trimethoxy OMe H O 87 84 190–192 —
21 4-F OEt H O 91 80 189–192 192–194 [24]
22 4-CF3 OEt H O 88 83 165–167 —
23 2-CF3 OEt H O 90 87 174–176 —
24 3-OH, 4-OCH3 CN COCH3 S 89 88 210–212 —
25 3-OCH3,4 - O H C N C O C H 3 S 84 87 190–195 —
26 4-OH CN COCH3 S 92 88 186–190 —
27 4-Cl CN COCH3 S 90 87 196–198 —
aThe reactions were carried out by grindingaromatic aldehyde (1.0mmol), 1,3-dicarbonyl compounds (1.0mmol), urea/thiourea/acetyl thiourea (2.0mmol),
and PPA or lithium-acetate (0.5mmol) in mortar and pestle at room temperature for 5–10 minutes (Method II).
from [(Ti − Tz)/(C − Tz)] × 100 = 50, which is the
drug concentration resulting in a 50% reduction in the net
protein increase (as measured by SRB staining) in control
cells during the drug incubation. The drug concentration
resulting in total growth inhibition (TGI) was calculated
from Ti = Tz. The LC50 (concentration of drug resulting
in a 50% reduction in the measured protein at the end of
the drug treatment as compared to that at the beginning)
indicating a net loss of cells following treatment is calculated
from
(Ti−Tz)
Tz

× 100 =− 50. (2)
Values were calculated for each of these three parameters
if the level of activity was reached; however, if the eﬀect was
not reached or was exceeded, the values for that parameter
were expressed as greater or less than the maximum or
minimum concentration tested.
The data of anticancer activity in terms of % control
growth at diﬀerent molar drug concentration are shown in
Tables 3 and 4. Unfortunately, all the evaluated compounds
showedpooractivityagainsthumancancercelllines.Growth
curves are presented in Figure 1.
Deﬁnitions. LC50: concentration of drug causing 50% cell
kill; GI50: concentration of drug causing 50% inhibition
of cell growth; TGI: concentration of drug causing total
inhibition of cell growth; ADR: adriamycin, positive control
compound. GI50 value of ≤10−6 molar (i.e., 1μmolar) or
≤ 10μg/mL is considered to demonstrate activity in case of
pure compounds. For extracts, GI50 value ≤ 20μg/mL is
considered to demonstrate activity Italic test values under
GI50 column indicate activity in Table 4.
3. Conclusions
This method oﬀers a simple, inexpensive, versatile, and envi-
ronment friendly approach to the synthesis of a library
of DHPMs. Lithium-acetate acts as an eﬃcient promoter
system of the Biginelli reaction yielding DHPMs in good-to-
excellentyields.Comparative promotereﬃciencyof lithium-
acetate and PPA to catalyze Biginelli condensation reaction is
alsostudiedunderneatconditionsandithasbeenfoundthatThe Scientiﬁc World Journal 5
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Figure 1: Invitro cytotoxic eﬀects of DHPM’s against two Human Cancer Cell Lines.
P P Aa c t sa sb e t t e rp r o m o t e ra sc o m p a r e dt ol i t h i u m - a c e t a t e .
The use of solvent-free conditions, short reaction times,
excellent yields, easy workup, and compatibility with various
functional groups makes the present catalytic reaction an
environmentally acceptable method for the synthesis of
dihydropyrimidinones and thiones.
4. Experimental
4.1. Chemical Analysis. Reagents and solvents were obtained
from commercial sources and used without further puriﬁca-
tion. Melting points were determined on a Toshniwal appa-
ratus. The spectral analyses of synthesized compounds have
been carried out at SAIF, Punjab University, Chandigarh.
Purity of all compounds was checked by TLC using “G-”
coated glass plates and benzene: ethyl acetate (9:1), benzene:
ethyl acetate: methanol (8.5:1.4:0.1) as eluent. IR spectra
were recorded in KBr on a Perkin Elmer Infrared RXI FTIR
spectrophotometer and 1H NMR spectra were recorded on
Bruker Avance II 400 NMR Spectrometer using DMSO-
d6 and CDCl3 as solvent and tetramethylsilane (TMS) as
internal reference standard. The room temperature means
30–40◦C. The obtained products were identiﬁed by com-
parison with authentic samples (synthesized by conventional
process) and from their spectral (1H NMR and IR) data and
themeltingpointswereconﬁrmedbycomparisonwiththose
reported in the literature.
4.2. Experimental Procedure for the Synthesis of Dihydropy-
rimidinones Using Solvents (Table 1). For comparison sake,
compound 1 was synthesized by stirring at room tempera-
ture in various solvents, for example, ethanol, toluene, water,
and acetonitrile for 7-8hrs using both lithium-acetate and
polyphosphoric acid as catalysts. A mixture of an aromatic
aldehyde (1mmol), β-dicarbonyl compound (1mmol),
urea/thiourea (2mmol), PPA/lithium-acetate (0.5mmol),
and solvent (5mL) was mixed in R.B. ﬂask and the mixture
was magnetically stirred at room temperature for the time
needed to complete the reaction (as monitored by TLC).
After completion, the reaction mixture was cooled to room
temperature and poured onto crushed ice, ﬁltered, and
recrystallized by using either ethanol or ethyl acetate and pet
ether (1:1) to aﬀo r dp u r ep r o d u c t .R e s u l t sa r es u m m a r i z e d
in Table 1.
4.3. General Procedure for the Synthesis of
Dihydropyrimidinones
Method I. A mixture of an aromatic aldehyde (1mmol),
β-dicarbonyl compound (1mmol), urea/thiourea (2mmol)
PPA/lithium-acetate (0.5mmol) was mixed in R.B. ﬂask and
the mixture was magnetically stirred at 70–80◦C for the time
needed to complete the reaction (as monitored by TLC).
The initial syrupy reaction mixture solidiﬁes within 30–35
minutes. After completion, the reaction mixture was cooled
to room temperature and poured onto crushed ice, ﬁltered,
and recrystallized by using either ethanol or ethyl acetate
and pet ether (1:1) to aﬀord pure product. The obtained
products were identiﬁed from their spectral (1HN M Ra n d
IR) data and their literature melting points.
Method II. A mixture of an aromatic aldehyde (1mmol),
β-dicarbonyl compound (1mmol), urea/thiourea (2mmol),
and PPA/lithium-acetate (0.5mmol) was ground together
for 5–10min. using a mortar and pestle of appropriate size.
The initial syrupy reaction mixture solidiﬁes within 15–20
minutes.Thesolidmasswasleftovernight,thenwashedwith
cold water, and puriﬁed either by recrystallization from ethyl
acetate and pet ether (1:1) or by column chromatography of
resulting crude material over silica gel using ethyl acetate and
pet ether (1.5:8.5) as the mobile phase. All the compounds
given in Table 2 are synthesized by both the methods and it
has been observed that yields of the synthesized compounds
obtainedbyMethodIis10–15%betterthanthatobtainedby
Method II.
Spectral data of newly synthesized compounds are given
below.
Compound13Ethyl-6-methyl-2-thioxo-4-(3-methoxyphenyl)-
1,2,3,4-tetrahydropyrimidin-5-carboxylate. IR (KBr): 3235,
3120, 2930, 2823, 1672, 1573, 1467, 1282, 1190, 1125, 723,
692cm−1; 1H NMR (DMSO-d6): 1.12 (t, 3H, OCH2CH3),
2.26 (s, 3H, 6-CH3), 3.77 (s, 3H, OCH3), 4.01 (q, 2H,8 The Scientiﬁc World Journal
OCH2CH3), 5.12 (s, 1H, CH), 6.58–7.03 (m, 4H, aromatic),
7.63 (s, 1H, N–H), 9.45 (s, 1H, N–H) ppm. Analytical
Calculation for C15H18N2O3S: C, 58.80; H, 5.92; N, 9.14.
Found: C, 58.62; H, 5.90; N, 9.17.
Compound 14 Ethyl-6-methyl-2-oxo-4-(2,4-dimethylphenyl)-
1,2,3,4-tetrahydropyrimidin-5-carboxylate. IR (KBr): 3234,
3110, 2933, 2833, 1703, 1649, 1511, 1455, 1276, 1175,
791cm−1; 1H NMR (DMSO-d6): 1.12 (t, 3H, OCH2CH3),
2.27 (s, 3H, 6-CH3), 2.35 (s, 3H, 2-CH3), 2.35 (s, 3H, 4-
CH3), 4.02 (q, 2H, OCH2CH3), 5.11 (s, 1H, CH), 6.74–6.82
(m, 3H, aromatic), 7.61 (s, 1H, N–H), 9.47 (s, 1H, N–H)
ppm. Analytical Calculation for C16H20N2O3: C, 66.65; H,
6.99; N, 9.72. Found: C, 66.46; H, 6.97; N, 9.75.
Compound 15 Ethyl-6-methyl-2-thioxo-4-(3,4-dimethylphen-
yl)-1,2,3,4-tetrahydropyrimidin-5-carboxylate. IR (KBr):
3313, 3171, 2989, 2842, 1668, 1575, 1460, 1373, 1332, 1259,
1192, 1118, 769cm−1; 1H NMR (DMSO-d6): 1.11 (t, 3H,
OCH2CH3), 2.28 (s, 3H, 6-CH3), 2.32 (s, 3H, 3-CH3), 2.33
(s, 3H, 4-CH3), 4.05 (q, 2H, OCH2CH3), 5.10 (s, 1H, CH),
6.72–6.81 (m, 3H, aromatic), 7.64 (s, 1H, N–H), 9.43 (s,
1H, N–H) ppm. Analytical Calculation for C16H20N2O2S: C,
63.13; H, 6.62; N, 9.20. Found: C, 63.24; H, 6.64; N, 9.17.
Compound 19 Methyl-6-methyl-2-thioxo-4-(3,4,5-trimethox-
yphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate. IR
(KBr): 3213, 3172, 3110, 2882, 1660, 1570, 1511, 1456, 1372,
1320, 1250, 1177, 1115, 765cm−1; 1H NMR (DMSO-d6):
2.36 (s, 3H, OCH3), 2.13 (s, 3H, 6-CH3), 3.81–4.22 (s, 9H,
Ar-OCH3), 5.12 (s, 1H, CH), 6.11–6.23 (d, 2H, aromatic),
7.76 (s, 1H, N–H), 9.42 (s, 1H, N–H) ppm. Analytical
Calculation for C16H20N2O5S: C, 54.53; H, 5.72; N, 7.95.
Found: C, 54.42; H, 5.71; N, 7.98.
Compound 20 Methyl 6-methyl-2-oxo-4-(3,4,5-trimethox-
yphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate. IR
(KBr): 3215, 3170, 3120, 2880, 1702, 1670, 1578, 1511, 1465,
1320, 1280, 1177, 1030, 762cm−1; 1H NMR (DMSO-d6):
2.32 (s, 3H, OCH3), 2.11 (s, 3H, 6-CH3), 3.67–4.32 (s, 9H,
Ar-OCH3), 5.13 (s, 1H, CH), 6.12–6.25 (d, 2H, aromatic),
7.82 (s, 1H, N–H), 9.43 (s, 1H, N–H) ppm. Analytical
Calculation for C16H20N2O6: C, 57.14; H, 5.99; N, 8.33
Found: C, 57.34; H, 5.97; N, 8.35.
Compound 22 Ethyl 6-methyl-2-oxo-4-(4-(triﬂuorometh-
yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate. IR
(KBr): 3244, 3122, 3109, 1720, 1690, 1571, 1460, 1312,
1270, 1077, 783cm−1; 1H NMR (DMSO-d6): 1.10 (t, 3H,
OCH2CH3), 2.23 (s, 3H, 6-CH3), 3.99 (q, 2H, OCH2CH3),
5.09 (s, 1H, CH), 6.18–6.27 (m, 4H, aromatic), 7.60 (s, 1H,
N–H), 9.39 (s, 1H, N–H) ppm. Analytical Calculation for
C15H15F3N2O3: C, 54.88; H, 4.61; N, 8.53. Found: C, 54.68;
H, 4.59; N, 8.56.
Compound 23 Ethyl 6-methyl-2-oxo-4-(2-(triﬂuorometh-
yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate. IR
(KBr): 3240, 3124, 3103, 1718, 1683, 1572, 1466, 1309,
1266, 1037, 769cm−1; 1H NMR (DMSO-d6): 1.10 (t, 3H,
OCH2CH3), 2.21 (s, 3H, 6-CH3), 3.98 (q, 2H, OCH2CH3),
5.02 (s, 1H, CH), 6.17–6.25 (m, 4H, aromatic), 7.62 (s, 1H,
N–H), 9.37 (s, 1H, N–H) ppm. Analytical Calculation for
C15H15F3N2O3: C, 54.88; H, 4.61; N, 8.53. Found: C, 54.70;
H, 4.59; N, 8.55.
Compound 24 1-Acetyl-6-(3-hydroxy-4-methoxyphenyl)-4-
methyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-5-carbonyl
cyanide. IR (KBr): 3251, 3432, 2225, 1728, 1381, 1250,
1115cm−1; 1H NMR (DMSO): 2.00 (s, 1H, NH), 2.02 (s,
3H, COCH3), 2.27 (s, 3H, 4-CH3), 3.73 (s, 3H, Ar-OCH3),
5.56 (s, 1H, cyclic CH), 6.23 (s, 1H, Ar-H), 6.23–7.10 (d, 2H,
Ar-H), 9.83 (s, 1H, ArOH) ppm. Analytical Calculation for
C16H15N3O4S: C, 55.64; H, 4.38; N, 12.17. Found: C, 55.55;
H, 4.40; N, 12.20.
Compound 25. 1-Acetyl-6-(4-hydroxy-3-methoxyphenyl)-
4-methyl-2-thioxo-1,2,3,6-tetrahydropyrimidine-5-carbonyl
cyanide. IR (KBr): 3254, 3435, 2233, 1722, 1382, 1240cm−1;
1H NMR (DMSO): 2.20 (s, 1H, NH), 2.23 (s, 3H, COCH3),
2.27 (s, 3H, 4-CH3), 3.77 (s, 3H, OCH3), 5.57 (s, 1H, cyclic
CH), 6.38–7.22 (m, 3H, Ar-H), 9.81 (s, 1H, ArOH) ppm.
Analytical Calculation for C16H15N3O4S: C, 55.64; H, 4.38;
N, 12.17. Found: C, 55.40; H, 4.36; N, 12.14.
Compound 26 1-Acetyl-6-(4-hydroxyphenyl)-4-methyl-2-
thioxo-1,2,3,6-tetrahydropyrimidine-5-carbonyl cyanide. IR
(KBr): 3252, 3433, 2235, 1725, 1383, 1251, 1121cm−1; 1H
NMR (DMSO): 2.40 (s, 1H, NH), 2.05 (s, 3H, COCH3), 2.27
(s, 3H, 4-CH3), 5.58 (s, 1H, cyclic CH), 6.23–7.10 (m, 4H,
Ar-H), 9.88 (s, 1H, ArOH) ppm. Analytical Calculation for
C15H13N3O3S: C, 57.13; H, 4.16; N, 13.33. Found: C, 56.95;
H, 4.15; N, 13.35.
Compound 27 1-Acetyl-6-(4-chlorophenyl)-4-methyl-2-
thioxo-1,2,3,6-tetrahydropyrimidine-5-carbonyl cyanide. IR
(KBr): 3255, 2735, 2231, 1721, 1380, 1242cm−1;1HN M R
(DMSO): 2.27 (s, 3H, 4-CH3), 2.40 (s, 1H, NH), 2.21 (s, 3H,
COCH3), 5.55 (s, 1H, cyclic CH), 6.38–7.22 (m, 4H, Ar-H)
ppm. Analytical Calculation for C15H12ClN3O2S: C, 53.97;
H, 3.62; N, 12.59. Found: C, 53.72; H, 3.64; N, 12.56.
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